Multivariate Development and Validation of a Stability-Indicating HPLC Method for the Determination of Glimepiride in Tablets

被引:8
作者
Bonfilio, Rudy [1 ]
Peres, Carolina [1 ]
Salgado, Herida R. N. [1 ]
de Araujo, Magali B. [2 ]
Tarley, Cesar R. T. [3 ]
机构
[1] Univ Estadual Paulista, Dept Farmacos & Medicamentos, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP, Brazil
[2] Univ Fed Alfenas, Dept Farm, BR-37130000 Alfenas, MG, Brazil
[3] Univ Fed Uberlandia, Inst Quim, BR-38400902 Uberlandia, MG, Brazil
关键词
PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; LC-MS-MS; HUMAN PLASMA; SPECTROPHOTOMETRIC METHOD; METFORMIN; PIOGLITAZONE; OPTIMIZATION; FORMULATION; URINE;
D O I
10.5740/jaoacint.11-065
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
This paper describes the multivariate development of a stability-indicating HPLC method for the quantification of glimepiride in pharmaceutical tablets. Full factorial design, Doehlert design, and response-surface methodology were used in conjunction with the desirability function approach. This procedure allowed the adequate separation of glimepiride from all degradant peaks in a short analysis time (about 9 min). This HPLC method uses potassium phosphate buffer (pH 6.5; 27.5 mmol/L)-methanol (34 + 66, v/v) mobile phase at a flow rate of 1.0 mL/min and UV detection at 228 nm. A Waters Symmetry (R) C18 column (250 x 4.6 mm, 5.0 mu m) at controlled room temperature (25 degrees C) was used as the stationary phase. The method was validated according to International Conference on Harmonization guidelines and demonstrated linearity from 2 to 40 mg/L glimepiride, selectivity, precision, accuracy, and robustness. The LOD and LOQ were 0.315 and 1.050 mg/L, respectively. The multivariate strategy adopted in this work can be successfully applied in routine laboratories because of its fast optimization without the additional cost of columns or equipment.
引用
收藏
页码:960 / 967
页数:8
相关论文
共 34 条
[1]   Analysis of glimepiride by using derivative UV spectrophotometric method [J].
Altinöz, S ;
Tekeli, D .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2001, 24 (03) :507-515
[2]  
[Anonymous], 2006, EUROPEAN PHARMACOPOE, P1976
[3]   LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride [J].
Bansal, Gulshan ;
Singh, Manjeet ;
Jindal, K. C. ;
Singh, Saranjit .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (03) :788-795
[4]   Development and Validation of an UV-Derivative Spectrophotometric Method for Determination of Glimepiride in Tablets [J].
Bonfilio, Rudy ;
de Araujo, Magali B. ;
Salgado, Herida R. N. .
JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, 2011, 22 (02) :292-299
[5]   Multivariate optimization and validation of an analytical methodology by RP-HPLC for the determination of losartan potassium in capsules [J].
Bonfilio, Rudy ;
Teixeira Tarley, Cesar Ricardo ;
Pereira, Gislaine Ribeiro ;
Nunes Salgado, Herida Regina ;
de Araujo, Magali Benjamim .
TALANTA, 2009, 80 (01) :236-241
[6]   A rapid and highly sensitive method for the determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pre-clinical pharmacokinetic study [J].
Chakradhar, Lagishetty ;
Kallem, Rajareddy ;
Karthik, Arumugam ;
Sundari, Bala Tripura ;
Ramesh, Srirangam ;
Mullangi, Ramesh ;
Srinivas, Nuggehally R. .
BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (01) :58-63
[7]  
DERRINGER G, 1980, J QUAL TECHNOL, V12, P214, DOI 10.1080/00224065.1980.11980968
[8]   Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl(R)): A double-blind comparison with glibenclamide [J].
Draeger, KE ;
WernickePanten, K ;
Lomp, HJ ;
Schuler, E ;
Rosskamp, R .
HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :419-425
[9]  
European Pharmacopoeia, 2008, EUR PHARM, P1975
[10]  
FDA, EL OR BOOK QUET